Ftse Mib
39.224,71
0,00%
DAX
22.794,11
1,78%
S&P 500
5.956,06
0,01%
NASDAQ
19.075,26
0,26%
Bitcoin
86.170,91
2,50%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Stoke Therapeutics Inc (STOK) Stoke Therapeutics Inc (STOK) Notizie

STOK

Stoke Therapeutics (STOK)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:STOK
DataOraFonteTitoloSimboloCompagnia
26/02/202522:30Business WireStoke Therapeutics to Present at Upcoming Investor Conferences in MarchNASDAQ:STOKStoke Therapeutics Inc
18/02/202522:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STOKStoke Therapeutics Inc
18/02/202514:00Business WireBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental ImpairmentsNASDAQ:STOKStoke Therapeutics Inc
08/01/202522:30Business WireStoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:STOKStoke Therapeutics Inc
07/01/202513:00Business WireStoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
06/01/202522:30Business WireStoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
27/12/202423:23Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:STOKStoke Therapeutics Inc
27/12/202423:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
24/12/202400:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:STOKStoke Therapeutics Inc
06/12/202418:00Business WireStoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
04/12/202413:00Business WireStoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
02/12/202414:00Business WireStoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual MeetingNASDAQ:STOKStoke Therapeutics Inc
14/11/202415:00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:STOKStoke Therapeutics Inc
05/11/202422:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STOKStoke Therapeutics Inc
05/11/202413:00Business WireStoke Therapeutics Reports Third Quarter Financial Results and Provides Business UpdatesNASDAQ:STOKStoke Therapeutics Inc
09/10/202422:16Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:STOKStoke Therapeutics Inc
23/09/202422:22Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:STOKStoke Therapeutics Inc
10/09/202413:00Business WireStoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
04/09/202414:00Business WireStoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business OfficerNASDAQ:STOKStoke Therapeutics Inc
03/09/202414:00Business WireStoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
03/09/202414:00Business WireStoke Therapeutics to Present at Upcoming Investor Conferences in SeptemberNASDAQ:STOKStoke Therapeutics Inc
16/08/202422:30Business WireStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:STOKStoke Therapeutics Inc
07/08/202413:00Business WireStoke Therapeutics Reports Second Quarter Financial Results and Provides Business UpdatesNASDAQ:STOKStoke Therapeutics Inc
13/06/202422:06Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:STOKStoke Therapeutics Inc
03/06/202422:30Business WireStoke Therapeutics to Present at Upcoming Investor Conferences in JuneNASDAQ:STOKStoke Therapeutics Inc
17/05/202422:12Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
06/05/202413:00Business WireStoke Therapeutics Reports First Quarter Financial Results and Provides Business UpdatesNASDAQ:STOKStoke Therapeutics Inc
29/04/202414:00Business WireStoke Therapeutics Appoints Thomas Leggett as Chief Financial OfficerNASDAQ:STOKStoke Therapeutics Inc
17/04/202414:00Business WireStoke Therapeutics Appoints Jason Hoitt as Chief Commercial OfficerNASDAQ:STOKStoke Therapeutics Inc
04/04/202422:30Business WireStoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:STOKStoke Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:STOK

La tua Cronologia

BIT
11COV
Bearer
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci